Study says VeriStrat predicts response but not survival benefit from erlotinib
A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit ...
Oct 15, 2012
0
0